Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M137,760Revenue $M42,159Net Margin (%)12.5Z-Score2.3
Enterprise Value $M152,039EPS $1.8Operating Margin %17.0F-Score5
P/E(ttm))26.1Cash Flow Per Share $0Pre-tax Margin (%)15.9Higher ROA y-yY
Price/Book2.110-y EBITDA Growth Rate %3.7Quick Ratio1.0Cash flow > EarningsY
Price/Sales3.35-y EBITDA Growth Rate %-1.6Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %8.0ROA % (ttm)7.3Higher Current Ratio y-yN
Dividend Yield %3.7Insider Buy (3m)0ROE % (ttm)12.6Less Shares Outstanding y-yN
Payout Ratio %89.0Shares Outstanding M2,642ROI % (ttm)4.2Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 52.15-2%Add 90.38%4,950,000
SNYPRIMECAP Management 2014-06-30 Add0.03%$51.23 - $54.54
($53.08)
$ 52.15-2%Add 21.59%3,011,646
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 52.15-2%Reduce -52.34%2,602,503
SNYScott Black 2014-06-30 Reduce-0.39%$51.23 - $54.54
($53.08)
$ 52.15-2%Reduce -27.57%178,985
SNYJohn Hussman 2014-06-30 Sold Out -0.09%$51.23 - $54.54
($53.08)
$ 52.15-2%Sold Out0
SNYScott Black 2014-03-31 Buy 1.4%$47.77 - $53.63
($50.64)
$ 52.153%New holding, 247100 sh.247,100
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 52.153%New holding, 2600000 sh.2,600,000
SNYHOTCHKIS & WILEY 2014-03-31 Add0.75%$47.77 - $53.63
($50.68)
$ 52.153%Add 65.83%9,804,594
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 52.153%Add 22.72%27,790,116
SNYNWQ Managers 2014-03-31 Reduce-0.17%$47.77 - $53.63
($50.68)
$ 52.153%Reduce -6.39%5,460,055
SNYHOTCHKIS & WILEY 2013-12-31 Add0.27%$48.75 - $54
($51.57)
$ 52.151%Add 23.53%5,912,375
SNYCharles Brandes 2013-12-31 Add0.2%$48.75 - $54
($51.57)
$ 52.151%Add 18.29%2,013,300
SNYNWQ Managers 2013-12-31 Add0.19%$48.75 - $54
($51.57)
$ 52.151%Add 7.52%5,832,760
SNYMario Gabelli 2013-12-31 Reduce$48.75 - $54
($51.57)
$ 52.151%Reduce -24.37%4,500
SNYJames Barrow 2013-09-30 Add1.29%$47.64 - $53.24
($50.87)
$ 52.152%Add 312.86%21,466,988
SNYHOTCHKIS & WILEY 2013-09-30 Add0.26%$47.64 - $53.24
($50.87)
$ 52.152%Add 31.71%4,786,334
SNYMario Gabelli 2013-09-30 Add$47.64 - $53.24
($50.87)
$ 52.152%Add 32.22%5,950
SNYMario Gabelli 2013-06-30 Buy $49.77 - $55.64
($53.28)
$ 52.15-2%New holding, 4500 sh.4,500
SNYNWQ Managers 2013-06-30 Reduce-1.16%$49.77 - $55.64
($53.28)
$ 52.15-2%Reduce -33.1%5,607,262
SNYCharles Brandes 2013-06-30 Reduce-0.26%$49.77 - $55.64
($53.28)
$ 52.15-2%Reduce -20.35%1,713,266
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SNY Bill Nygren 2014-06-304,950,0000.191.9+90.38%
SNY PRIMECAP Management 2014-06-303,011,6460.110.18+21.59%
SNY Charles Brandes 2014-06-302,182,3050.081.4+5.28%
SNY James Barrow 2014-06-3028,526,8021.082+2.65%
SNY Ken Fisher 2014-06-3013,079,5750.51.5+1.18%
SNY Mario Gabelli 2014-06-304,50000
SNY Warren Buffett 2014-06-303,905,8750.150.19
SNY Dodge & Cox 2014-06-3043,549,9091.652.2-0.26%
SNY HOTCHKIS & WILEY 2014-06-309,772,0610.371.8-0.33%
SNY Jean-Marie Eveillard 2014-06-30608,5680.020.08-0.36%
SNY Third Avenue Management 2014-06-3013,40200.01-14.67%
SNY Scott Black 2014-06-30178,9850.011.4-27.57%
SNY NWQ Managers 2014-06-302,602,5030.11.4-52.34%
SNY John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-03-25Buy344,448$66.88-22.02view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67579.92view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      The MS Global Franchise Fund's Top Five Stocks Sep 10 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
      The French Government Collapses…and French Stocks Rally. What Gives? Aug 26 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
      Sanofi Doesn´t Look Good in Absolute Valuation Method Aug 21 2014 


      More From Other Websites
      Amicus Reports Additional Positive Data on Fabry Therapy Oct 20 2014
      Sanofi and Regeneron Dose Patients in Dupilumab Study Oct 20 2014
      Amgen Sues Sanofi and Regeneron over PCSK9 Candidate Oct 20 2014
      3 Drugs Stocks Dragging The Industry Down Oct 20 2014
      MannKind: Goldman Sachs Sees 'Limited Upside' Oct 20 2014
      10:36 am Sanofi-Aventis's Genzyme reports results from two phase III studies added to U.S. Label of... Oct 20 2014
      Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio Oct 20 2014
      US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s... Oct 20 2014
      Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis Oct 20 2014
      Two Tribes Go to War: Amgen Sues Regeneron for Patent Infringement Oct 17 2014
      Regeneron Eye Drug Beats Rivals While Amgen Sues Oct 17 2014
      [video] Positive for Regeneron: Cramer Oct 17 2014
      Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex... Oct 16 2014
      Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex... Oct 16 2014
      New Survey Finds Differences In Attitudes About Diabetes Based On Age Oct 15 2014
      A Drug Regrew A Little Girl's Missing Bones. How Much Should That Cost? Oct 14 2014
      Weyerhaeuser, Elizabeth Arden, Eni, SAP and Sanofi highlighted as Zacks Bull and Bear of the Day Oct 14 2014
      Alnylam Drug Scores Against Rare Nerve Disease Oct 13 2014
      Eurozone May Enter Triple-Dip Recession: 3 Stocks to Dump Oct 13 2014
      Fed to the rescue…again! Oct 08 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK